We are live on ! Find out more
DCOY

Decoy Therapeutics
DCOY

10 hedge funds and large institutions have $170K invested in Decoy Therapeutics in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more funds holding

Funds holding: 8 → 10 (+2)

0% less ownership

Funds ownership: 0.01% → 0% (-0%)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

25% less capital invested

Capital invested by funds: $227K → $170K (-$57K)

Holders
10
Holders Change
+2
Holders Change %
+25%
% of All Funds
0.15%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$17K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$11K
3
TSS
Two Sigma Securities
New York
+$8.98K
4
Renaissance Technologies
Renaissance Technologies
New York
+$998

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$94.8K
2
HKAM
Horizon Kinetics Asset Management
New York
-$998

DCOY Hedge Fund Activity: Q4 2023 in Review

10 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Decoy Therapeutics (DCOY) for Q4 2023, worth a combined $170K — down 25% from $227K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new DCOY positions and 0 closed out — a net gain of 2 holders — while 2 added to existing stakes and 2 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $17K. The largest seller was Armistice Capital, cutting an estimated $94.8K.

  • 10 institutional investors held Decoy Therapeutics (DCOY) as of Q4 2023, up from 8 in Q3 2023.
  • Funds reported $170K of Decoy Therapeutics stock for Q4 2023, down 25% quarter-over-quarter.
  • 2 funds opened new Decoy Therapeutics positions in Q4 2023 and 0 closed out, a net change of +2 holders.
  • The largest Decoy Therapeutics buyer in Q4 2023 was Citadel Advisors, an estimated $17K added.
  • The largest Decoy Therapeutics seller in Q4 2023 was Armistice Capital, an estimated $94.8K sold.

Based on aggregated 13F filings for Q4 2023.